If this is your first visit, be sure to check out the FAQ in HCMA Announcements. You may have to register before you can post: click the register link above to proceed. To start viewing messages, select the forum that you want to visit from the selection below. Your Participation in this message board is strictly voluntary. Information and comments on the message board do not necessarily reflect the feelings, opinions, or positions of the Hypertrophic Cardiomyopathy Association. At no time should participants to this board substitute information within for individual medical advice. The Hypertrophic Cardiomyopathy Association shall not be liable for any information provided herein. All participants in this board should conduct themselves in a professional and respectful manner. Failure to do so will result in suspension or termination. The moderators of the message board working with the HCMA will be responsible for notifying participants if they have violated the rules of conduct for the board. Moderators or HCMA staff may edit any post to ensure it conforms with the rules of the board or may delete it. This community is welcoming to all those with HCM we ask that you remember each user comes to the board with information and a point of view that may differ from that which you hold, respect is critical, please post respectfully. Thank you

Announcement

Collapse
No announcement yet.

Medical device company announces results of study

Collapse

About the Author

Collapse

hcma Find out more about hcma
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

  • Medical device company announces results of study

    Copyright 2005 Life Science Weekly via NewsRx.com & NewsRx.net
    Life Science Weekly

    January 25, 2005

    SECTION: EXPANDED REPORTING; Pg. 302

    LENGTH: 408 words

    HEADLINE: CARDIOMYOPATHY;
    Medical device company announces results of study in hypertrophic cardiomyopathy

    BODY:

    Researchers at Zargis Medical Corp., a majority-owned subsidiary of Speedus
    Corp. (SPDE), announced the results of a clinical study involving hypertrophic
    cardiomyopathy (HCM)

    The study demonstrated that a computer-assisted heart sounds analysis
    algorithm could identify those patients flagged by a cardiologist as having
    apical systolic murmurs that were louder on standing than reclining, a cardinal
    sign of obstructive HCM. HCM is implicated in one third of the cases of sudden
    cardiac death in young athletes.

    The study involved 12 volunteer subjects who had been previously diagnosed
    with HCM, of which 4 reported obstructive HCM. Twenty-second recordings were
    obtained at each of 4 standard auscultatory locations in 2 postures: standing
    and reclining. Detailed auscultatory findings were derived by listening to the
    heart sound recordings by a cardiologist who was blinded to the study design.

    The recordings were analyzed by a computer algorithm that detects and
    identifies heart sounds and murmurs, and provides quantitative measures of the
    heart sounds. The algorithm results were compared with the auscultatory findings
    provided by the cardiologist.

    A high degree of concordance between the cardiologists' auscultatory
    findings and computer analyses was obtained. The systolic energy was found to
    correlate well with judgments of the relative loudness of murmurs in different
    postures. The 3 subjects who were flagged by the cardiologist as having apical
    systolic murmurs that were louder on standing were identified by the algorithm
    as having apical systolic murmurs with higher systolic energies in the standing
    posture.

    These results demonstrate that there are detectable acoustic features of
    heart sound recordings that are associated with auscultatory findings of
    obstructive HCM.

    Zargis Medical Corp. was formed in January 2001 when Siemens Corporate
    Research Inc., a subsidiary of Siemens AG (SI), and Speedus Corp. (SPDE)
    co-invested in Zargis to further develop and commercially market an advanced
    acoustic technology for detecting abnormalities identified through analysis of
    heart sounds. Based in Princeton, New Jersey, Zargis is developing diagnostic
    decision support products and services for primary care physicians,
    cardiologists and other healthcare professionals.

    This article was prepared by Life Science Weekly editors from staff and
    other reports. Copyright 2005, Life Science Weekly via NewsRx.com &
    NewsRx.net.

    LOAD-DATE: January 21, 2005

Today's Birthdays

Collapse

Working...
X